{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T22:31:02Z","timestamp":1766269862866,"version":"3.48.0"},"reference-count":48,"publisher":"Walter de Gruyter GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_dmdi-2023-0007_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Radioactive iodine therapy is considered for patients with certain clinicopathological factors that predict a significant risk of recurrence, distant metastases of thyroid cancer or disease-specific mortality. The aim of the study was to investigate the association between polymorphisms of genes, products of which are involved in the processes of\u00a0DNA damage response and autophagy, and the adverse reactions of radioiodine therapy in thyroid cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dmdi-2023-0007_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The study included 181 patients (37 men, 144 women; median age 56 [41; 66.3] years) with histologically confirmed thyroid cancer and a history of thyroidectomy who received radioiodine therapy.\n                      <jats:italic>NFKB1<\/jats:italic>\n                      ,\n                      <jats:italic>ATM<\/jats:italic>\n                      ,\n                      <jats:italic>ATG16L2<\/jats:italic>\n                      ,\n                      <jats:italic>ATG10<\/jats:italic>\n                      ,\n                      <jats:italic>TGFB1<\/jats:italic>\n                      , and\n                      <jats:italic>TNF<\/jats:italic>\n                      polymorphisms were determined by allele-specific realtime-PCR.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dmdi-2023-0007_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The frequency of adverse reactions was the following: gastrointestinal symptoms\u00a0\u2013 57.9\u202f%, local symptoms\u00a0\u2013 65.8\u202f%, cerebral symptoms\u00a0\u2013 46.8\u202f%, fatigue\u00a0\u2013 54.4\u202f%; signs of sialoadenitis six months after radioiodine therapy\u00a0\u2013 25.2\u202f%. TT genotype carriers of\n                      <jats:italic>ATG10<\/jats:italic>\n                      rs1864183 had higher frequency of gastrointestinal symptoms (vs. CC+CT), the CC genotype carriers of\n                      <jats:italic>ATG10<\/jats:italic>\n                      rs10514231 had significantly more frequent cerebral symptoms (vs. CT+TT), as well as AA genotype carriers of\n                      <jats:italic>TGFB1<\/jats:italic>\n                      rs1800469 (vs. AG+GG). CC genotype of\n                      <jats:italic>ATG10<\/jats:italic>\n                      rs10514231 increased the incidence of radioiodine-induced fatigue, whereas GA genotype of the\n                      <jats:italic>ATM<\/jats:italic>\n                      rs11212570 had a protective role against fatigue.\n                      <jats:italic>TGFB1<\/jats:italic>\n                      rs1800469 was associated with signs of sialoadenitis six months after radioiodine therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dmdi-2023-0007_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Genetic factors may contribute to the occurrence of adverse reactions of radioiodine therapy in thyroid cancer patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/dmdi-2023-0007","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T02:50:26Z","timestamp":1688007026000},"source":"Crossref","is-referenced-by-count":3,"title":["Genetic markers associated with adverse reactions of radioiodine therapy in thyroid cancer patients"],"prefix":"10.1515","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3278-5941","authenticated-orcid":false,"given":"Natalia P.","family":"Denisenko","sequence":"first","affiliation":[{"name":"Research Laboratory of Neuroendocrine Tumors , Centre for Personalized Medicine , Saint-Petersburg , Russia"},{"name":"Research Institute of Molecular and Personalized Medicine , Russian Medical Academy of Continuous Professional Education , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3194-4410","authenticated-orcid":false,"given":"Anastasia A.","family":"Kachanova","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0227-2651","authenticated-orcid":false,"given":"Ivan V.","family":"Sychev","sequence":"additional","affiliation":[{"name":"Department of Faculty Therapy with courses of Physiotherapy and Exercise Therapy, Medicine Institute , Ogarev Mordovia State University , Saransk , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5031-0088","authenticated-orcid":false,"given":"Gregory N.","family":"Shuev","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oksana M.","family":"Perfilieva","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8052-4984","authenticated-orcid":false,"given":"Reis H.","family":"Mukhamadiev","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0802-4229","authenticated-orcid":false,"given":"Ruslan E.","family":"Kazakov","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6828-3831","authenticated-orcid":false,"given":"Olga I.","family":"Milyutina","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4789-2718","authenticated-orcid":false,"given":"Olga V.","family":"Konenkova","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2595-353X","authenticated-orcid":false,"given":"Sergey A.","family":"Ryzhkin","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena M.","family":"Zhmaeva","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey L.","family":"Kirienko","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2295-7167","authenticated-orcid":false,"given":"Dmitriy V.","family":"Ivashchenko","sequence":"additional","affiliation":[{"name":"Research Laboratory of Neuroendocrine Tumors , Centre for Personalized Medicine , Saint-Petersburg , Russia"},{"name":"Research Institute of Molecular and Personalized Medicine , Russian Medical Academy of Continuous Professional Education , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2043-5848","authenticated-orcid":false,"given":"Irina V.","family":"Bure","sequence":"additional","affiliation":[{"name":"Research Laboratory of Neuroendocrine Tumors , Centre for Personalized Medicine , Saint-Petersburg , Russia"},{"name":"Research Institute of Molecular and Personalized Medicine , Russian Medical Academy of Continuous Professional Education , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander S.","family":"Ametov","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0995-1801","authenticated-orcid":false,"given":"Irina V.","family":"Poddubnaya","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9307-4994","authenticated-orcid":false,"given":"Karin B.","family":"Mirzaev","sequence":"additional","affiliation":[{"name":"Research Laboratory of Neuroendocrine Tumors , Centre for Personalized Medicine , Saint-Petersburg , Russia"},{"name":"Research Institute of Molecular and Personalized Medicine , Russian Medical Academy of Continuous Professional Education , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4496-3680","authenticated-orcid":false,"given":"Dmitry A.","family":"Sychev","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education , Moscow , Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"key":"2025122008375584304_j_dmdi-2023-0007_ref_001","doi-asserted-by":"crossref","unstructured":"Haddad, RI, Bischoff, L, Ball, D, Bernet, V, Blomain, E, Busaidy, NL, et al.. Thyroid carcinoma, Version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2022;20:925\u201351. https:\/\/doi.org\/10.6004\/jnccn.2022.0040.","DOI":"10.6004\/jnccn.2022.0040"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_002","doi-asserted-by":"crossref","unstructured":"Smanik, PA, Liu, Q, Furminger, TL, Ryu, K, Xing, S, Mazzaferri, EL, et al.. Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 1996;226:339\u201345. https:\/\/doi.org\/10.1006\/bbrc.1996.1358.","DOI":"10.1006\/bbrc.1996.1358"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_003","doi-asserted-by":"crossref","unstructured":"Levy, O, De la Vieja, A, Carrasco, N. The Na+\/I- symporter (NIS): recent advances. J Bioenerg Biomembr 1998;30:195\u2013206. https:\/\/doi.org\/10.1023\/a:1020577426732.","DOI":"10.1023\/A:1020577426732"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_004","unstructured":"Solans, R, Bosch, JA, Galofr\u00e9, P, Porta, F, Rosell\u00f3, J, Selva-O\u2019Callagan, A, et al.. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 2001;42:738\u201343."},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_005","unstructured":"Chung, J-K. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med 2002;43:1188\u2013200."},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_006","doi-asserted-by":"crossref","unstructured":"Spitzweg, C, Joba, W, Schriever, K, Goellner, JR, Morris, JC, Heufelder, AE. Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. J Clin Endocrinol Metab 1999;84:4178\u201384. https:\/\/doi.org\/10.1210\/jcem.84.11.6117.","DOI":"10.1210\/jc.84.11.4178"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_007","doi-asserted-by":"crossref","unstructured":"Zeraatpishe, A, Oryan, S, Bagheri, MH, Pilevarian, AA, Malekirad, AA, Baeeri, M, et al.. Effects of Melissa officinalis L. on oxidative status and DNA damage in subjects exposed to long-term low-dose ionizing radiation. Toxicol Ind Health 2011;27:205\u201312. https:\/\/doi.org\/10.1177\/0748233710383889.","DOI":"10.1177\/0748233710383889"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_008","doi-asserted-by":"crossref","unstructured":"Baum, BJ. Principles of saliva secretion. Ann N Y Acad Sci 1993;694:17\u201323. https:\/\/doi.org\/10.1111\/j.1749-6632.1993.tb18338.x.","DOI":"10.1111\/j.1749-6632.1993.tb18338.x"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_009","doi-asserted-by":"crossref","unstructured":"Kutta, H, Kampen, U, Sagowski, C, Brenner, W, Bohuslavizki, K-H, Paulsen, F. Amifostine is a potent radioprotector of salivary glands in radioiodine therapy. Structural and ultrastructural findings. Strahlenther Onkol 2005;181:237\u201345. https:\/\/doi.org\/10.1007\/s00066-005-1353-3.","DOI":"10.1007\/s00066-005-1353-3"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_010","doi-asserted-by":"crossref","unstructured":"Silberstein, EB. Reducing the incidence of 131I-induced sialadenitis: the role of pilocarpine. J Nucl Med 2008;49:546\u20139. https:\/\/doi.org\/10.2967\/jnumed.107.049411.","DOI":"10.2967\/jnumed.107.049411"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_011","doi-asserted-by":"crossref","unstructured":"Hoelzer, S, Steiner, D, Bauer, R, Reiners, C, Farahati, J, Hundahl, SA, et al.. Current practice of radioiodine treatment in the management of differentiated thyroid cancer in Germany. Eur J Nucl Med 2000;27:1465\u201372. https:\/\/doi.org\/10.1007\/s002590000333.","DOI":"10.1007\/s002590000333"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_012","doi-asserted-by":"crossref","unstructured":"Kielbassa, AM, Hinkelbein, W, Hellwig, E, Meyer-L\u00fcckel, H. Radiation-related damage to dentition. Lancet Oncol 2006;7:326\u201335. https:\/\/doi.org\/10.1016\/s1470-2045(06)70658-1.","DOI":"10.1016\/S1470-2045(06)70658-1"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_013","doi-asserted-by":"crossref","unstructured":"Dardano, A, Ballardin, M, Ferdeghini, M, Lazzeri, E, Traino, C, Caraccio, N, et al.. Anticlastogenic effect of Ginkgo biloba extract in Graves\u2019 disease patients receiving radioiodine therapy. J Clin Endocrinol Metab 2007;92:4286\u20139. https:\/\/doi.org\/10.1210\/jc.2007-0597.","DOI":"10.1210\/jc.2007-0597"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_014","unstructured":"Hern\u00e1ndez-Jardines, A, Molina, B, del Castillo, V, Papadakis, M, Rivera, T, Azor\u00edn, J, et al.. Detection of short-term chromosomal damage due to therapeutic 131I exposure in patients with thyroid cancer. Rev Invest Clin 2010;62:31\u20138."},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_015","doi-asserted-by":"crossref","unstructured":"Iarmarcovai, G, Ceppi, M, Botta, A, Orsi\u00e8re, T, Bonassi, S. Micronuclei frequency in peripheral blood lymphocytes of cancer patients: a meta-analysis. Mutat Res 2008;659:274\u201383. https:\/\/doi.org\/10.1016\/j.mrrev.2008.05.006.","DOI":"10.1016\/j.mrrev.2008.05.006"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_016","doi-asserted-by":"crossref","unstructured":"Van Nostrand, D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid 2009;19:1381\u201391. https:\/\/doi.org\/10.1089\/thy.2009.1611.","DOI":"10.1089\/thy.2009.1611"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_017","doi-asserted-by":"crossref","unstructured":"Luster, M, Clarke, SE, Dietlein, M, Lassmann, M, Lind, P, Oyen, WJG, et al.. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008;35:1941\u201359. https:\/\/doi.org\/10.1007\/s00259-008-0883-1.","DOI":"10.1007\/s00259-008-0883-1"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_018","doi-asserted-by":"crossref","unstructured":"Mandel, SJ, Mandel, L. Radioactive iodine and the salivary glands. Thyroid 2003;13:265\u201371. https:\/\/doi.org\/10.1089\/105072503321582060.","DOI":"10.1089\/105072503321582060"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_019","doi-asserted-by":"crossref","unstructured":"Rubino, C, de Vathaire, F, Dottorini, ME, Hall, P, Schvartz, C, Couette, JE, et al.. Second primary malignancies in thyroid cancer patients. Br J\u00a0Cancer 2003;89:1638\u201344. https:\/\/doi.org\/10.1038\/sj.bjc.6601319.","DOI":"10.1038\/sj.bjc.6601319"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_020","doi-asserted-by":"crossref","unstructured":"Bourguignon, MH, Gisone, PA, Perez, MR, Michelin, S, Dubner, D, Giorgio, MDi, et al.. Genetic and epigenetic features in radiation sensitivity. Part II: implications for clinical practice and radiation protection. Eur J Nucl Med Mol Imaging 2005;32:351\u201368. https:\/\/doi.org\/10.1007\/s00259-004-1731-6.","DOI":"10.1007\/s00259-004-1731-6"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_021","doi-asserted-by":"crossref","unstructured":"Jackson, SP, Bartek, J. The DNA-damage response in human biology and disease. Nature 2009;461:1071\u20138. https:\/\/doi.org\/10.1038\/nature08467.","DOI":"10.1038\/nature08467"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_022","doi-asserted-by":"crossref","unstructured":"Fei, P, El-Deiry, WS. P53 and radiation responses. Oncogene 2003;22:5774\u201383. https:\/\/doi.org\/10.1038\/sj.onc.1206677.","DOI":"10.1038\/sj.onc.1206677"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_023","doi-asserted-by":"crossref","unstructured":"Jackson, SP. DNA-dependent protein kinase. Int J Biochem Cell Biol 1997;29:935\u20138. https:\/\/doi.org\/10.1016\/s1357-2725(97)00006-x.","DOI":"10.1016\/S1357-2725(97)00006-X"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_024","doi-asserted-by":"crossref","unstructured":"Tibbetts, RS, Brumbaugh, KM, Williams, JM, Sarkaria, JN, Cliby, WA, Shieh, SY, et al.. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 1999;13:152\u20137. https:\/\/doi.org\/10.1101\/gad.13.2.152.","DOI":"10.1101\/gad.13.2.152"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_025","doi-asserted-by":"crossref","unstructured":"Shiloh, Y. ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev 2001;11:71\u20137. https:\/\/doi.org\/10.1016\/s0959-437x(00)00159-3.","DOI":"10.1016\/S0959-437X(00)00159-3"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_026","doi-asserted-by":"crossref","unstructured":"Kastan, MB, Lim, DS, Kim, ST, Yang, D. ATM--a key determinant of multiple cellular responses to irradiation. Acta Oncol 2001;40:686\u20138. https:\/\/doi.org\/10.1080\/02841860152619089.","DOI":"10.1080\/02841860152619089"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_027","doi-asserted-by":"crossref","unstructured":"Hickson, I, Zhao, Y, Richardson, CJ, Green, SJ, Martin, NMB, Orr, AI, et al.. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004;64:9152\u20139. https:\/\/doi.org\/10.1158\/0008-5472.can-04-2727.","DOI":"10.1158\/0008-5472.CAN-04-2727"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_028","doi-asserted-by":"crossref","unstructured":"Singh, K, Matsuyama, S, Drazba, JA, Almasan, A. Autophagy-dependent senescence in response to DNA damage and chronic apoptotic stress. Autophagy 2012;8:236\u201351. https:\/\/doi.org\/10.4161\/auto.8.2.18600.","DOI":"10.4161\/auto.8.2.18600"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_029","doi-asserted-by":"crossref","unstructured":"Cortez, D, Guntuku, S, Qin, J, Elledge, SJ. ATR and ATRIP: partners in checkpoint signaling. Science 2001;294:1713\u20136. https:\/\/doi.org\/10.1126\/science.1065521.","DOI":"10.1126\/science.1065521"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_030","doi-asserted-by":"crossref","unstructured":"Singh, R, Shankar, BS, Sainis, KB. TGF-\u03b21-ROS-ATM-CREB signaling axis in macrophage mediated migration of human breast cancer MCF7 cells. Cell Signal 2014;26:1604\u201315. https:\/\/doi.org\/10.1016\/j.cellsig.2014.03.028.","DOI":"10.1016\/j.cellsig.2014.03.028"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_031","doi-asserted-by":"crossref","unstructured":"Levine, AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323\u201331. https:\/\/doi.org\/10.1016\/s0092-8674(00)81871-1.","DOI":"10.1016\/S0092-8674(00)81871-1"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_032","doi-asserted-by":"crossref","unstructured":"Ko, LJ, Prives, C. p53: puzzle and paradigm. Genes Dev 1996;10:1054\u201372. https:\/\/doi.org\/10.1101\/gad.10.9.1054.","DOI":"10.1101\/gad.10.9.1054"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_033","doi-asserted-by":"crossref","unstructured":"Thomasova, D, Mulay, SR, Bruns, H, Anders, H-J. p53-independent roles of MDM2 in NF-\u03baB signaling: implications for cancer therapy, wound healing, and autoimmune diseases. Neoplasia 2012;14:1097\u2013101. https:\/\/doi.org\/10.1593\/neo.121534.","DOI":"10.1593\/neo.121534"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_034","doi-asserted-by":"crossref","unstructured":"Aggarwal, BB, Sung, B. NF-\u03baB in cancer: a matter of life and death. Cancer Discov 2011;1:469\u201371. https:\/\/doi.org\/10.1158\/2159-8290.cd-11-0260.","DOI":"10.1158\/2159-8290.CD-11-0260"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_035","doi-asserted-by":"crossref","unstructured":"Bauerle, KT, Schweppe, RE, Haugen, BR. Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion. Mol Cancer 2010;9:117. https:\/\/doi.org\/10.1186\/1476-4598-9-117.","DOI":"10.1186\/1476-4598-9-117"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_036","doi-asserted-by":"crossref","unstructured":"Chen, F, Yin, S, Zhu, J, Jia, L, Zhang, H, Yang, C, et al.. Effects of nuclear factor-\u03baB on the uptake of 131iodine and apoptosis of thyroid carcinoma cells. Mol Med Rep 2018;17:4959\u201364. https:\/\/doi.org\/10.3892\/mmr.2018.8481.","DOI":"10.3892\/mmr.2018.8481"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_037","doi-asserted-by":"crossref","unstructured":"Yan, HQ, Zhang, D, Shi, YY, You, X, Shi, L, Li, Q, et al.. Ataxia-telangiectasia mutated activation mediates tumor necrosis factor-alpha induced MMP-13 up-regulation and metastasis in lung cancer cells. Oncotarget 2016;7:62070\u201383. https:\/\/doi.org\/10.18632\/oncotarget.11386.","DOI":"10.18632\/oncotarget.11386"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_038","doi-asserted-by":"crossref","unstructured":"Katayama, M, Kawaguchi, T, Berger, MS, Pieper, RO. DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 2007;14:548\u201358. https:\/\/doi.org\/10.1038\/sj.cdd.4402030.","DOI":"10.1038\/sj.cdd.4402030"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_039","doi-asserted-by":"crossref","unstructured":"Dyavaiah, M, Rooney, JP, Chittur, SV, Lin, Q, Begley, TJ. Autophagy-dependent regulation of the DNA damage response protein ribonucleotide reductase 1. Mol Cancer Res 2011;9:462\u201375. https:\/\/doi.org\/10.1158\/1541-7786.mcr-10-0473.","DOI":"10.1158\/1541-7786.MCR-10-0473"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_040","doi-asserted-by":"crossref","unstructured":"Liu, J, Tang, X, Shi, F, Li, C, Zhang, K, Liu, J, et al.. Genetic polymorphism contributes to 131 I radiotherapy-induced toxicities in patients with differentiated thyroid cancer. Pharmacogenomics 2018;19:1335\u201344. https:\/\/doi.org\/10.2217\/pgs-2018-0070.","DOI":"10.2217\/pgs-2018-0070"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_041","doi-asserted-by":"crossref","unstructured":"Yang, Z, Liu, Z. Potentially functional variants of autophagy\u2010related genes are associated with the efficacy and toxicity of radiotherapy in patients with nasopharyngeal carcinoma. Mol Genet Genomic Med 2019;7:1\u20138. https:\/\/doi.org\/10.1002\/mgg3.1030.","DOI":"10.1002\/mgg3.1030"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_042","doi-asserted-by":"crossref","unstructured":"Naranjo, CA, Busto, U, Sellers, EM, Sandor, P, Ruiz, I, Roberts, EA, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239\u201345. https:\/\/doi.org\/10.1038\/clpt.1981.154.","DOI":"10.1038\/clpt.1981.154"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_043","unstructured":"Paillahueque Vel\u00e1squez, G. Efectos secundarios a corto y mediano plazo del tratamiento con 131I en pacientes con c\u00e1ncer diferenciado de tiroides. Santiago: Universidad de Chile; 2018. Available from: https:\/\/repositorio.uchile.cl\/handle\/2250\/149434."},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_044","unstructured":"Ord\u00faz, S, Lisen, O. Incidencia de los efectos adversos tempranos y evaluaci\u00f3n de calidad de vida en los pacientes que reciben terapia con radioyodo para el tratamiento del c\u00e1ncer de tiroides en un servicio de referencia de medicina nuclear en Colombia. Bucaramanga: Universidad aut\u00f3noma de bucaramanga; 2019. Available from: http:\/\/hdl.handle.net\/20.500.12749\/7219."},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_045","doi-asserted-by":"crossref","unstructured":"Van Nostrand, D, Freitas, J. Side effects of 131I for ablation and treatment of well-differentiated thyroid carcinoma. In: Thyroid cancer. Totowa, NJ: Humana Press; 2006. p.\u00a0459\u201383. Available from: http:\/\/link.springer.com\/10.1007\/978-1-59259-995-0_52.","DOI":"10.1007\/978-1-59259-995-0_52"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_046","doi-asserted-by":"crossref","unstructured":"Hyer, S, Kong, A, Pratt, B, Harmer, C. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol 2007;19:83\u20136. https:\/\/doi.org\/10.1016\/j.clon.2006.11.005.","DOI":"10.1016\/j.clon.2006.11.005"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_047","doi-asserted-by":"crossref","unstructured":"Burmeister, LA, du Cret, RP, Mariash, CN. Local reactions to radioiodine in the treatment of thyroid cancer. Am J Med 1991;90:217\u201322. https:\/\/doi.org\/10.1016\/0002-9343(91)90545-9.","DOI":"10.1016\/0002-9343(91)90545-9"},{"key":"2025122008375584304_j_dmdi-2023-0007_ref_048","doi-asserted-by":"crossref","unstructured":"Denisenko, NP, Shuev, GN, Mukhamadiev, RH, Perfilieva, OM, Kazakov, RE, Kachanova, AA, et al.. Genetic markers associated with resistance to radioiodine therapy in thyroid cancer patients: prospective cohort study. J Mod Oncol 2022;24:345\u201350. Available from: https:\/\/modernonco.orscience.ru\/1815-1434\/article\/view\/110799. https:\/\/doi.org\/10.26442\/18151434.2022.3.201867.","DOI":"10.26442\/18151434.2022.3.201867"}],"container-title":["Drug Metabolism and Personalized Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmdi-2023-0007\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmdi-2023-0007\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T08:46:30Z","timestamp":1766220390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmdi-2023-0007\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":48,"alternative-id":["10.1515\/dmdi-2023-0007"],"URL":"https:\/\/doi.org\/10.1515\/dmdi-2023-0007","relation":{},"ISSN":["2363-8915"],"issn-type":[{"type":"electronic","value":"2363-8915"}],"subject":[],"published":{"date-parts":[[2023,6,30]]}}}